Azenta (AZTA) AI Stock Analysis

• Market Cap: $950.25M
• Dividend Yield: N/A
• Average Volume (3M): 948.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: -9.49%
• EPS Growth: 58.97%
• Country: US
• Employees: 3,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.09
• Shares Outstanding: 46,061,527
• 10 Day Avg. Volume: 1,028,897
• 30 Day Avg. Volume: 948,241
• PEG Ratio: 0.39
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 2.21
• P/FCF Ratio: 34.28
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 1.21
• Enterprise Value/Gross Profit: 2.67
• Enterprise Value/Ebitda: 13.35
• 1Y Price Target: $39.67
• Price Target Upside: 40.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.79
• Revenue Forecast (FY): $618.57M

• Rating: 56 Neutral
• Price Target: $22.00 ▼(-21.93% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

AZTA scores as a mid-range setup driven by strong financial flexibility (low leverage, substantial cash, and positive recent cash flow) and reaffirmed improvement targets, but weighed down by very weak technical momentum and ongoing profitability/margin pressures. Valuation is also less supportive due to losses (negative P/E) and no dividend yield provided.

Positive Factors

Balance sheet strength

Azenta's extremely low leverage and large equity base provide durable financial flexibility. With substantial liquidity and no meaningful debt, the company can fund capex, strategic M&A, share repurchases, and weather cyclical softness without near-term solvency pressure, supporting multi‑quarter execution.

Recurring, diversified revenue streams

The business mixes capital equipment, recurring consumables, and outsourced Multiomics services, producing resilient revenue drivers. Strong gross margins (~46%) and recent top-line rebound suggest product economics that can support sustainable cash generation if utilization and service volumes normalize.

Strategic portfolio actions and M&A

Targeted M&A (UK Biocentre) expands European biorepository scale and automation capabilities, while the B Medical divestiture simplifies the portfolio and frees capital. These structural moves sharpen focus on core sample management and Multiomics, improving size, margins and long‑term market positioning.

Negative Factors

Sustained unprofitable operations

Although revenue has rebounded, the company remains unprofitable with negative EBIT and roughly -10% net margins. Persistent operating losses and volatile results mean Azenta must convert gross margin and revenue gains into consistent operating leverage to achieve durable profitability and justify growth investments.

Margin headwinds and remediation costs

Material gross margin compression and remediation charges from automated storage quality issues impose recurring execution risk. The $3–$5M remediation and ~360bp gross‑margin decline highlight product reliability and delivery weaknesses that can delay planned adjusted EBITDA expansion and impair cash conversion over multiple quarters.

End‑market and regional demand volatility

North American softness, lab underutilization and structural declines in Sanger sequencing show end‑market sensitivity. Regional and product demand shifts can depress utilization and consumable repeatability, making revenue and margin recovery dependent on variable academic/biopharma budgets and technology transitions.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

How the Company Makes Money

Azenta makes money primarily by selling life-sciences products and services used to store, manage, process, and analyze biological samples. A key revenue stream comes from its Sample Management Solutions activities, which include (1) selling automated cold-storage and sample handling systems (capital equipment revenue), (2) recurring revenue from consumables used with those systems (e.g., sample tubes, plates, and related labware), and (3) service revenue tied to installation, maintenance, and support of deployed systems. Another major revenue stream comes from its Multiomics and other life-sciences services, where customers pay for outsourced lab services (such as genomic sequencing and related sample/data services). These services typically generate revenue on a per-project or per-sample basis, with repeat business driven by ongoing research programs and long-term customer relationships. If specific material partnerships or contract terms are required for a more granular breakdown, null.

Azenta Financial Statement Overview

Summary

Financials are mixed: a very strong, low-leverage balance sheet (debt-to-equity ~0.03) and currently positive operating/free cash flow support resilience, but profitability remains pressured with negative EBIT and net income and a history of uneven results. Improving TTM revenue growth (+19.1%) and solid gross margin (~46%) help, but the business is still in a prove-it phase on sustainable earnings.

Income Statement

AZTA shows improving top-line momentum in TTM (Trailing-Twelve-Months), with revenue up 19.1% and a solid gross margin (~46%), indicating good underlying product/service economics. However, profitability remains pressured: EBIT and net income are still negative (net margin about -10%), and results have been volatile over the last few years (including a much deeper loss in 2024). Overall, the revenue rebound and healthy gross margin are positives, but the continued operating losses and inconsistency keep the score below average.

Balance Sheet

The balance sheet is a clear strength. Leverage is very low (debt-to-equity around 0.03 in both the latest annual period and TTM), supported by a large equity base relative to assets. The main weakness is that returns remain negative due to ongoing net losses (negative return on equity), but from a solvency and financial flexibility standpoint, AZTA appears well-positioned.

Cash Flow

Cash generation is generally positive in the most recent periods, with positive operating cash flow and positive free cash flow in both the latest annual period and TTM (Trailing-Twelve-Months). That said, free cash flow declined meaningfully in TTM (free cash flow growth -19.3%), and cash flow performance has been uneven historically (including very large negative operating and free cash flow in 2022). Overall, current cash flow is supportive, but the recent step-down and historical volatility temper confidence.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	595.19M	593.82M	573.45M	665.07M	555.50M	513.70M
Gross Profit	269.63M	270.28M	254.62M	233.26M	230.62M	214.51M
EBITDA	53.93M	54.07M	71.62M	55.15M	48.35M	9.94M
Net Income	-57.82M	-55.76M	-164.90M	-14.26M	-428.96M	110.75M
Balance Sheet
Total Assets	2.07B	2.06B	2.10B	2.89B	3.72B	1.82B
Cash, Cash Equivalents and Short-Term Investments	412.05M	340.92M	462.09M	1.02B	1.57B	227.51M
Total Debt	108.92M	111.17M	70.68M	60.44M	49.23M	94.77M
Total Liabilities	359.60M	330.70M	331.07M	351.22M	352.74M	494.18M
Stockholders Equity	1.71B	1.73B	1.77B	2.53B	3.36B	1.33B
Cash Flow
Free Cash Flow	30.93M	38.32M	12.35M	-33.60M	-543.48M	97.05M
Operating Cash Flow	63.23M	72.18M	49.74M	5.83M	-466.05M	149.86M
Investing Cash Flow	-130.78M	-90.46M	224.74M	431.38M	1.47B	-146.35M
Financing Cash Flow	-7.10M	-9.59M	-659.21M	-840.46M	-62.76M	-25.91M

Azenta Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Negative. The current price of 28.18 is above the 20-day moving average (MA) of 24.90, below the 50-day MA of 31.32, and below the 200-day MA of 31.52, indicating a bearish trend. The MACD of -2.72 indicates Positive momentum. The RSI at 26.31 is Positive, neither overbought nor oversold. The STOCH value of 21.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTA.

Azenta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	64 Neutral	$943.30M	-95.19	-3.40%	―	-18.82%	92.56%
ATRC	60 Neutral	$1.45B	-165.01	-2.43%	―	15.80%	26.94%
AZTA	56 Neutral	$950.25M	-24.75	-3.39%	―	-9.49%	58.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	46 Neutral	$864.99M	-14.54	-23.24%	―	-32.42%	-540.37%
QDEL	45 Neutral	$1.13B	-1.76	-46.45%	―	-3.43%	38.98%
SMTI	42 Neutral	$167.28M	-2.26	-127.51%	―	30.55%	-340.19%

Azenta Corporate Events

Azenta Acquires UK Biocentre to Expand European Biorepository

On March 4, 2026, Azenta announced that its subsidiary Azenta UK Ltd had completed the acquisition of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services, for total consideration of GBP 20.5 million, including up to GBP 1.8 million in contingent payments. Founded in 2014, UK Biocentre generated about GBP 15.3 million in revenue in the 12 months to September 30, 2025 and will continue operating under its existing name.

The deal is designed to expand Azenta’s biorepository and sample management footprint in Europe by using UK Biocentre as a regional operational hub complementing its Griesheim, Germany facility and serving pharmaceutical, biotech, academic and public health clients. Azenta expects the transaction to be modestly dilutive to its 2026 adjusted EBITDA margin by about 35 basis points but accretive to organic revenue growth and margin expansion in 2027 and 2028, while enhancing its ability to deliver large-scale, automated biorepository capabilities such as the 16-million-sample BioArc Ultra platform and reinforcing its positioning at the center of key life sciences workflows.

The most recent analyst rating on (AZTA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta Shareholders Reaffirm Board, Pay Plans and Auditor

At its annual meeting on January 28, 2026, Azenta, Inc. stockholders voted to re-elect all nominated directors, signaling continued support for the company’s current board composition and governance. Investors also backed, on an advisory basis, the compensation packages for named executive officers, approved an amendment to the 2020 Equity Incentive Plan to add 2,750,000 shares for future equity grants, and ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent auditor for the 2026 fiscal year, collectively reinforcing management’s strategic flexibility in incentivizing employees and maintaining auditor continuity for stakeholders.

The most recent analyst rating on (AZTA) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta divests B Medical Systems to streamline portfolio

On December 29, 2025, Azenta announced that its affiliate Azenta Germany GmbH has entered into a definitive agreement to sell the company’s Luxembourg-based B Medical Systems business, a global manufacturer and distributor of medical refrigeration devices, to THELEMA S.À R.L. for US$63 million, with the transaction expected to close on or before March 31, 2026. Management described the divestiture as a major step in simplifying Azenta’s portfolio to concentrate on its highest-impact core capabilities, with proceeds earmarked to strengthen the business and support long-term profitable value creation for shareholders, while William Blair and Taylor Wessing advised Azenta on the deal.

The most recent analyst rating on (AZTA) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.